Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario

被引：5
作者：
Meyers, Brandon M. [1 ]
Knox, Jennifer J. [2 ]
Cosby, Roxanne [3 ]
Beecroft, J. R. [4 ]
Chan, Kelvin K. W. [5 ]
Coburn, Natalie [5 ]
Feld, Jordan J. [6 ]
Jonker, Derek [7 ]
Mahmud, Aamer [8 ]
Ringash, Jolie [9 ,10 ]
机构：
[1] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] McMaster Univ, Dept Oncol, Program Evidence Based Care, Hamilton, ON, Canada
[4] Mt Sinai Hosp, Dept Med Imaging, Toronto, ON, Canada
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
[7] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[8] Canc Ctr Southeastern Ontario, Kingston, ON, Canada
[9] Princess Margaret Canc Ctr, Toronto, ON, Canada
[10] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
来源：
CANADIAN LIVER JOURNAL | 2021年 / 4卷 / 03期
关键词：
hepatocellular carcinoma; non-surgical treatment; systematic review; systemic therapy; tyrosine kinase inhibitor; PHASE-II TRIAL; DOUBLE-BLIND; TRANSARTERIAL CHEMOEMBOLIZATION; PLUS SORAFENIB; OPEN-LABEL; 1ST-LINE THERAPY; 2ND-LINE TREATMENT; MULTICENTER; PLACEBO; HCC;
D O I：
10.3138/canlivj-2020-0039
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
BACKGROUND: Hepatocellular carcinoma (HCC) is a global health problem, accounting for 4.7% of all new cancer cases and 8.2% of all cancer deaths worldwide in 2018. Resection and transplantation are the only modalities that offer a cure for HCC; however, most patients are diagnosed at an advanced stage, precluding these curative treatments. A number of local (ie, ablative therapies) and/or local-regional therapies (ie, chemo-embolization) are used and followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy compared with these standards is not well known. METHODS: Literature searches (1/2000 to 1/2020 or 1/2005 to 1/2020, depending on the specific systematic review question) were conducted, including MEDLINE, Embase and the Cochrane Database of Systematic Reviews. RESULTS: Over 30,000 articles were identified. In total, 49 studies were included in the systematic review. CONCLUSIONS: There is no evidence to support the addition of sorafenib to any local or regional therapy. First-line systemic therapy options for unresectable or metastatic HCC include sorafenib, lenvatinib, and atezolizumab + bevacizumab. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment.
引用
收藏
页码：257 / 274
页数：18
相关论文
共 56 条
[51]   A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma [J].
Yen, Chia-Jui ;
Kim, Tae-You ;
Feng, Yin-Hsun ;
Chao, Yee ;
Lin, Deng-Yn ;
Ryoo, Baek-Yeol ;
Huang, Dennis Chin-Lun ;
Schnell, David ;
Hocke, Julia ;
Loembe, Arsene-Bienvenu ;
Cheng, Ann-Lii .
LIVER CANCER, 2018, 7 (02) :165-178
[52]   Randomized phase II trial of intravenous R05137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168). [J].
Yen, Chia-Jul ;
Daniele, Bruno ;
Kudo, Masatoshi ;
Merle, Philippe ;
Park, Joong-Won ;
Ross, Paul J. ;
Peron, Jean-Marie ;
Ebert, Oliver ;
Chan, Stephen Lam ;
Tung, Ronnie ;
Poon, Ping ;
Colombo, Massimo ;
Okusaka, Takuji ;
Ryoo, Baek-Yeol ;
Minguez, Beatriz ;
Tanaka, Takayoshi ;
Ohtomo, Toshihiko ;
Rutman, Olga ;
Chen, Ya-Chi ;
Lee, Reuy-min ;
Abou-Alfa, Ghassan K. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[53]   Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Zhu, Andrew X. ;
Kang, Yoon-Koo ;
Yen, Chia-Jui ;
Finn, Richard S. ;
Galle, Peter R. ;
Llovet, Josep M. ;
Assenat, Eric ;
Brandi, Giovanni ;
Pracht, Marc ;
Lim, Ho Yeong ;
Rau, Kun-Ming ;
Motomura, Kenta ;
Ohno, Izumi ;
Merle, Philippe ;
Daniele, Bruno ;
Shin, Dong Bok ;
Gerken, Guido ;
Borg, Christophe ;
Hiriart, Jean-Baptiste ;
Okusaka, Takuji ;
Morimoto, Manabu ;
Hsu, Yanzhi ;
Abada, Paolo B. ;
Kudo, Masatoshi .
LANCET ONCOLOGY, 2019, 20 (02) :282-296
[54]   Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial [J].
Zhu, Andrew X. ;
Park, Joon Oh ;
Ryoo, Baek-Yeol ;
Yen, Chia-Jui ;
Poon, Ronnie ;
Pastorelli, Davide ;
Blanc, Jean-Frederic ;
Chung, Hyun Cheol ;
Baron, Ari D. ;
Pfiffer, Tulio Eduardo Flesch ;
Okusaka, Takuji ;
Kubackova, Katerina ;
Trojan, Jorg ;
Sastre, Javier ;
Chau, Ian ;
Chang, Shao-Chun ;
Abada, Paolo B. ;
Yang, Ling ;
Schwartz, Jonathan D. ;
Kudo, Masatoshi .
LANCET ONCOLOGY, 2015, 16 (07) :859-870
[55]   SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma [J].
Zhu, Andrew X. ;
Rosmorduc, Olivier ;
Evans, T. R. Jeffry ;
Ross, Paul J. ;
Santoro, Armando ;
Carrilho, Flair Jose ;
Bruix, Jordi ;
Qin, Shukui ;
Thuluvath, Paul J. ;
Llovet, Josep M. ;
Leberre, Marie-Aude ;
Jensen, Markus ;
Meinhardt, Gerold ;
Kang, Yoon-Koo .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :559-566
[56]   Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial [J].
Zhu, Andrew X. ;
Kudo, Masatoshi ;
Assenat, Eric ;
Cattan, Stephane ;
Kang, Yoon-Koo ;
Lim, Ho Yeong ;
Poon, Ronnie T. P. ;
Blanc, Jean-Frederic ;
Vogel, Arndt ;
Chen, Chao-Long ;
Dorval, Etienne ;
Peck-Radosavljevic, Markus ;
Santoro, Armando ;
Daniele, Bruno ;
Furuse, Junji ;
Jappe, Annette ;
Perraud, Kevin ;
Anak, Oezlem ;
Sellami, Dalila B. ;
Chen, Li-Tzong .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (01) :57-67
123456